GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0837
-0.0037 (-4.23%)
Oct 2, 2026, 5:35 PM CET
GenSight Biologics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -15.34 | -12.04 | -14 | -26.22 | -27.63 | -28.62 |
Depreciation & Amortization | 0.5 | 0.47 | 1.06 | 2.18 | 1.06 | 0.93 |
Stock-Based Compensation | 0.29 | 0.39 | 0.78 | 0.59 | -3.36 | 4.83 |
Other Operating Activities | 2.83 | 1.02 | -1.65 | -3.66 | 0.09 | 0.88 |
Change in Accounts Receivable | - | - | - | -0 | 0.76 | -0.7 |
Change in Accounts Payable | -2.47 | -0.52 | 0.16 | -2.23 | -2.15 | 2.4 |
Change in Other Net Operating Assets | 5.92 | 1.51 | 0.72 | 4.69 | -2.52 | 3.14 |
Operating Cash Flow | -8.27 | -9.17 | -12.94 | -24.66 | -33.75 | -17.14 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.07 | -0 | -0 | -0.01 | -0.25 | -0.03 |
Investment in Securities | 0.24 | 0.19 | 0.02 | 0.22 | 0.42 | 0.02 |
Other Investing Activities | -0 | -0 | -0 | - | - | - |
Investing Cash Flow | 0.17 | 0.18 | 0.02 | 0.21 | 0.17 | -0.02 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | 14.18 | 10.8 | - |
Long-Term Debt Repaid | - | -1.25 | -2.9 | -1.87 | -8.68 | -3.65 |
Net Debt Issued (Repaid) | -1.08 | -1.25 | -2.9 | 12.31 | 2.12 | -3.65 |
Issuance of Common Stock | 6.42 | 6.18 | 15.81 | 3.96 | 0 | 30 |
Repurchase of Common Stock | -0.04 | - | -0.03 | -0.1 | -0.19 | -0.31 |
Other Financing Activities | 4.32 | 4.02 | 0.65 | -0.31 | -1.83 | -2.3 |
Financing Cash Flow | 9.62 | 8.94 | 13.54 | 15.86 | 0.1 | 23.74 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.12 | 0.01 | -0.29 | 0.12 | -0.19 | -0.24 |
Miscellaneous Cash Flow Adjustments | 0 | - | 0 | - | - | -0 |
Net Cash Flow | 1.4 | -0.05 | 0.33 | -8.48 | -33.68 | 6.35 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -8.34 | -9.17 | -12.94 | -24.67 | -34.01 | -17.17 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | -1407.06% | -492.88% | -832.42% | -698.97% | -222.74% |
Free Cash Flow Per Share | -0.05 | -0.06 | -0.14 | -0.51 | -0.73 | -0.38 |
Levered Free Cash Flow | -13.39 | -7.24 | -6.69 | -14.13 | -29.49 | -13.79 |
Unlevered Free Cash Flow | -10.61 | -5.44 | -5.72 | -12.16 | -27.83 | -12.43 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.21 | 0.21 | 0.28 | 0.37 | 1.87 | 0.84 |
Change in Working Capital | 3.46 | 0.99 | 0.87 | 2.45 | -3.92 | 4.84 |